The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Subscribe To Our Newsletter & Stay Updated
